3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Gastrointestinal
1
Conditions
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
pembrolizumab
43
Nivolumab
29
atezolizumab
11
Specimen Handling
10
Cyclophosphamide
10
Bevacizumab
10
Paclitaxel
9
Magnetic Resonance Spectroscopy
9
cabozantinib
7
Ipilimumab
7
Carboplatin
7
fludarabine
6
durvalumab
6
avelumab
6
Sunitinib
6
Sorafenib
6
Oxaliplatin
6
Fluorouracil
6
Docetaxel
6
spartalizumab
5
sargramostim
5
Leucovorin
5
Cisplatin
5
Cetuximab
5
aldesleukin
4
Trastuzumab
4
Radiosurgery
4
Psychiatric Rehabilitation
4
Irinotecan
4
Gemcitabine
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
bexmarilimab
×
Gastrointestinal
×
Clear all
NCT05104905
2022-05-11
RENACOL
Faron Pharmaceuticals Ltd
Phase 1/2
Withdrawn